The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects With Type 2 Diabetes

Cell Metabolism - United States
doi 10.1016/j.cmet.2013.08.005
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Recombinant Human Leptin Treatment Does Not Improve Insulin Action in Obese Subjects With Type 2 Diabetes

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2011English

Different Aetiologies of Type 2 (Non-Insulin-Dependent) Diabetes Mellitus in Obese and Non-Obese Subjects

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
1991English

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

PLoS ONE
Multidisciplinary
2013English

Metabolic Effects of Oral Vitamin D Supplementation as an Adjuvant Therapy on Subjects With Type 2 Diabetes

International Journal of Basic & Clinical Pharmacology
2019English

Canagliflozin: Effects in Overweight and Obese Subjects Without Diabetes Mellitus

Obesity
NutritionEndocrinologyDieteticsMedicineMetabolismDiabetes
2013English

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2016English

Non-Obese Type 2 Diabetes Animals Models

2012English

Diabetes Remission After Nonsurgical Intensive Lifestyle Intervention in Obese Patients With Type 2 Diabetes

Journal of Diabetes Research
EndocrinologyMetabolismDiabetes
2015English

The Role of FGF21 in Type 1 Diabetes and Its Complications

International Journal of Biological Sciences
Applied MicrobiologyEvolutionEcologyDevelopmental BiologyCell BiologyMolecular BiologySystematicsBehaviorBiotechnology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy